FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W29771769> ?p ?o ?g. }

• W29771769 endingPage "200" @default.
• W29771769 startingPage "193" @default.
• W29771769 abstract "With the use of a continuous spectrophotometric assay and initial rates determined by the method of Waley [Biochem. J. (1981) 193, 1009-1012] methotrexate was found to be a non-competitive inhibitor, with Ki(intercept) = 72 microM and Ki(slope) = 41 microM, of 5-aminoimidazole-4-carboxamide ribotide transformylase, whereas a polyglutamate of methotrexate containing three gamma-linked glutamate residues was a competitive inhibitor, with Ki = 3.15 microM. Pentaglutamates of folic acid and 10-formylfolic acid were also competitive inhibitors of the transformylase, with Ki values of 0.088 and 1.37 microM respectively. Unexpectedly, the pentaglutamate of 10-formyldihydrofolic acid was a good substrate for the transformylase, with a Km of 0.51 microM and a relative Vmax. of 0.72, which compared favourably with a Km of 0.23 microM and relative Vmax. of 1.0 for the tetrahydro analogue. An analysis of the progress curve of the transformylase-catalysed reaction with the above dihydro coenzyme revealed that the pentaglutamate of dihydrofolic acid was a competitive product inhibitor, with Ki = 0.14 microM. The continuous spectrophotometric assay for adenosine deaminase based on change in the absorbance at 265 nm was shown to be valid with adenosine concentrations above 100 microM, which contradicts a previous report [Murphy, Baker, Behling & Turner (1982) Anal. Biochem. 122, 328-337] that this assay was invalid above this concentration. With the spectrophotometric assay, 5-aminoimidazole-4-carboxamide riboside was found to be a competitive inhibitor of adenosine deaminase, with (Ki = 362 microM), whereas the ribotide was a competitive inhibitor of 5'-adenylate deaminase, with Ki = 1.01 mM. Methotrexate treatment of susceptible cells results in (1) its conversion into polyglutamates, (2) the accumulation of oxidized folate polyglutamates, and (3) the accumulation of 5-aminoimidazole-4-carboxamide riboside and ribotide. The above metabolic events may be integral elements producing the cytotoxic effect of this drug by (1) producing tighter binding of methotrexate to folate-dependent enzymes, (2) producing inhibitors of folate-dependent enzymes from their tetrahydrofolate coenzymes, and (3) trapping toxic amounts of adenine nucleosides and nucleotides as a result of inhibition of adenosine deaminase and 5'-adenylate deaminase respectively." @default.
• W29771769 created "2016-06-24" @default.
• W29771769 creator A5003088154 @default.
• W29771769 creator A5011190253 @default.
• W29771769 creator A5019947516 @default.
• W29771769 date "1986-05-15" @default.
• W29771769 modified "2023-10-09" @default.
• W29771769 title "Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide" @default.
• W29771769 cites W105336363 @default.
• W29771769 cites W109933903 @default.
• W29771769 cites W1484304115 @default.
• W29771769 cites W1509115195 @default.
• W29771769 cites W1533310140 @default.
• W29771769 cites W1558399150 @default.
• W29771769 cites W1562507217 @default.
• W29771769 cites W1565483916 @default.
• W29771769 cites W1573060772 @default.
• W29771769 cites W157532068 @default.
• W29771769 cites W1688909813 @default.
• W29771769 cites W1709825510 @default.
• W29771769 cites W1964789691 @default.
• W29771769 cites W1969469300 @default.
• W29771769 cites W1990993335 @default.
• W29771769 cites W2013730796 @default.
• W29771769 cites W2025733817 @default.
• W29771769 cites W2037886242 @default.
• W29771769 cites W2040564398 @default.
• W29771769 cites W2044809194 @default.
• W29771769 cites W2055923490 @default.
• W29771769 cites W2057386668 @default.
• W29771769 cites W2063797973 @default.
• W29771769 cites W2069069778 @default.
• W29771769 cites W2076158544 @default.
• W29771769 cites W2081623629 @default.
• W29771769 cites W2126859200 @default.
• W29771769 cites W2177063286 @default.
• W29771769 cites W2196852790 @default.
• W29771769 cites W2401696156 @default.
• W29771769 cites W2463240385 @default.
• W29771769 cites W2525004700 @default.
• W29771769 cites W2531893580 @default.
• W29771769 cites W2969273703 @default.
• W29771769 cites W4229575904 @default.
• W29771769 cites W984065349 @default.
• W29771769 cites W301147989 @default.
• W29771769 doi "https://doi.org/10.1042/bj2360193" @default.
• W29771769 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1146805" @default.
• W29771769 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2431676" @default.
• W29771769 hasPublicationYear "1986" @default.
• W29771769 type Work @default.
• W29771769 sameAs 29771769 @default.
• W29771769 citedByCount "193" @default.
• W29771769 countsByYear W297717692012 @default.
• W29771769 countsByYear W297717692013 @default.
• W29771769 countsByYear W297717692014 @default.
• W29771769 countsByYear W297717692015 @default.
• W29771769 countsByYear W297717692016 @default.
• W29771769 countsByYear W297717692017 @default.
• W29771769 countsByYear W297717692018 @default.
• W29771769 countsByYear W297717692019 @default.
• W29771769 countsByYear W297717692020 @default.
• W29771769 countsByYear W297717692021 @default.
• W29771769 countsByYear W297717692022 @default.
• W29771769 countsByYear W297717692023 @default.
• W29771769 crossrefType "journal-article" @default.
• W29771769 hasAuthorship W29771769A5003088154 @default.
• W29771769 hasAuthorship W29771769A5011190253 @default.
• W29771769 hasAuthorship W29771769A5019947516 @default.
• W29771769 hasBestOaLocation W297717692 @default.
• W29771769 hasConcept C104317684 @default.
• W29771769 hasConcept C150757390 @default.
• W29771769 hasConcept C165912504 @default.
• W29771769 hasConcept C181199279 @default.
• W29771769 hasConcept C185592680 @default.
• W29771769 hasConcept C2776328115 @default.
• W29771769 hasConcept C2776991684 @default.
• W29771769 hasConcept C2778327999 @default.
• W29771769 hasConcept C2909627636 @default.
• W29771769 hasConcept C34628245 @default.
• W29771769 hasConcept C512185932 @default.
• W29771769 hasConcept C55493867 @default.
• W29771769 hasConcept C71240020 @default.
• W29771769 hasConcept C86803240 @default.
• W29771769 hasConcept C98892162 @default.
• W29771769 hasConceptScore W29771769C104317684 @default.
• W29771769 hasConceptScore W29771769C150757390 @default.
• W29771769 hasConceptScore W29771769C165912504 @default.
• W29771769 hasConceptScore W29771769C181199279 @default.
• W29771769 hasConceptScore W29771769C185592680 @default.
• W29771769 hasConceptScore W29771769C2776328115 @default.
• W29771769 hasConceptScore W29771769C2776991684 @default.
• W29771769 hasConceptScore W29771769C2778327999 @default.
• W29771769 hasConceptScore W29771769C2909627636 @default.
• W29771769 hasConceptScore W29771769C34628245 @default.
• W29771769 hasConceptScore W29771769C512185932 @default.
• W29771769 hasConceptScore W29771769C55493867 @default.
• W29771769 hasConceptScore W29771769C71240020 @default.
• W29771769 hasConceptScore W29771769C86803240 @default.

• next